Treatment of Relapsed Acute Myeloid Leukemia.
Thol F, Ganser A.
Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5.
A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K.
Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482.
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I.
Int J Hematol. 2022 Jun;115(6):762-777. doi: 10.1007/s12185-022-03353-5. Epub 2022 May 9.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M.
JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605.
Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Li R, Wang Z, Zhang Y, Guo M, Ni X, Chen J, Chen L, Gao L, Gong S, Tang G, Yang J, Wang J.
Ann Hematol. 2023 Jan;102(1):89-97. doi: 10.1007/s00277-022-05061-w. Epub 2022 Dec 21.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F.
Haematologica. 2024 Nov 1;109(11):3543-3556. doi: 10.3324/haematol.2024.285057.
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis J.
Blood Adv. 2025 Aug 12;9(15):3853-3864. doi: 10.1182/bloodadvances.2025015797.
Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N, Kosiorek H, Slack JL, Lonzo ML, Greipp PT, Khera N, Kelemen K.
Biol Blood Marrow Transplant. 2017 May;23(5):782-789. doi: 10.1016/j.bbmt.2017.02.003. Epub 2017 Feb 9.
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
O'Connor D, Valle-Inclán JE, Conde L, Bloye G, Rahman S, Costa JR, Bartram J, Adams S, Wright G, Elrick H, Wall K, Dyer S, Howell C, Jigoulina G, Herrero J, Cortes-Ciriano I, Moorman AV, Mansour MR.
Blood. 2024 Mar 7;143(10):933-937. doi: 10.1182/blood.2023021906.
